- Home
- HBI vs ADPT Comparison
HBI vs ADPT Comparison
Compare HBI & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBI
- ADPT
- Stock Information
- Founded
- HBI 1901
- ADPT 2009
- Country
- HBI United States
- ADPT United States
- Employees
- HBI N/A
- ADPT N/A
- Industry
- HBI Clothing/Shoe/Accessory Stores
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HBI Consumer Discretionary
- ADPT Health Care
- Exchange
- HBI Nasdaq
- ADPT Nasdaq
- Market Cap
- HBI 2.3B
- ADPT 2.6B
- IPO Year
- HBI 2006
- ADPT 2019
- Fundamental
- Price
- HBI $6.63
- ADPT $19.62
- Analyst Decision
- HBI Hold
- ADPT Strong Buy
- Analyst Count
- HBI 5
- ADPT 10
- Target Price
- HBI $6.60
- ADPT $16.60
- AVG Volume (30 Days)
- HBI 7.6M
- ADPT 2.4M
- Earning Date
- HBI 11-06-2025
- ADPT 11-05-2025
- Dividend Yield
- HBI N/A
- ADPT N/A
- EPS Growth
- HBI N/A
- ADPT N/A
- EPS
- HBI 0.93
- ADPT N/A
- Revenue
- HBI $3,531,625,000.00
- ADPT $252,754,000.00
- Revenue This Year
- HBI $1.61
- ADPT $36.43
- Revenue Next Year
- HBI N/A
- ADPT $12.31
- P/E Ratio
- HBI $7.12
- ADPT N/A
- Revenue Growth
- HBI 4.55
- ADPT 42.57
- 52 Week Low
- HBI $3.96
- ADPT $5.29
- 52 Week High
- HBI $9.10
- ADPT $20.76
- Technical
- Relative Strength Index (RSI)
- HBI 52.46
- ADPT 67.55
- Support Level
- HBI $6.42
- ADPT $13.28
- Resistance Level
- HBI $6.68
- ADPT $20.76
- Average True Range (ATR)
- HBI 0.17
- ADPT 1.12
- MACD
- HBI 0.01
- ADPT 0.58
- Stochastic Oscillator
- HBI 80.25
- ADPT 84.89
About HBI Hanesbrands Inc.
Hanesbrands manufactures basic and athletic apparel under brands including Hanes, Playtex, Maidenform, Bali, Berlei, and Bonds. The company sells wholesale to discount, midmarket, and department store retailers as well as direct to consumers through stores and e-commerce. Hanesbrands is vertically integrated, as it produces nearly 75% of its products in company-controlled factories in more than three dozen nations. Hanesbrands distributes products in the Americas and Asia-Pacific. The company was founded in 1901 and is based in Winston-Salem, North Carolina. Hanesbrands has agreed to be acquired by Canadian rival Gildan.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).